Treatment of Gastrointestinal Endocrine Tumours with Interferon-α and Octreotide

References

• Strander HA. Clinical effects of interferon therapy with special emphasis on antitumor efficacy. Acta Oncol 1989; 28: 355–62
   PubMed Web of Science ®Google Scholar
• Öberg K, Funa K, Aim G. Effects of leucocyte interferon on clinical symptoms and hormone levels in patients with midgut carcinoid tumors and carcinoid syndrome. NEYM 1983; 309: 129–32
   PubMed Web of Science ®Google Scholar
• Hanssen L E, Schrumpf E, Kolbenstvedt A N, Tausjø J, Dolva LØ. Recombinant α-2 interferon with or without hepatic artery embolization in the treatment of midgut carcinoid tumours—A preliminary report. Acta Oncol 1989; 28: 439–43
   PubMed Web of Science ®Google Scholar
• Nobin A, Lindblom A, Månsson B, Sundberg M. Interferon treatment in patients with malignant carcinoids. Acta Oncol 1989; 28: 445–9
   PubMed Web of Science ®Google Scholar
• Brazeau P, Vale W, Burgus R, et al. Hpothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77–9
   PubMed Web of Science ®Google Scholar
• Reichlin S. Somatostatin. N Engl J Med 1983; 309: 1501, 1556–63, 1495
   PubMedGoogle Scholar
• Arnold R, Creutzfeldt W. Hemmung der pentagastrin-induzierten Säuresekretion des Magens beim Menschen durch Somatostatin. Dtsch Med Wochenschr 1975; 100: 1014–16
   PubMed Web of Science ®Google Scholar
• Creutzfeldt W, Lankisch P-G, Folsch UR. Hemmung der Secretin- und Cholecystokinin-Pancreozymin-induzierten Saft-und Enzymsekretion des Pankreas und der Gallenblasenkon-traktion bei Menschen durch Somatostatin. Dtsch Med Wochenschr 1975; 100: 1135–8
   PubMed Web of Science ®Google Scholar
• Krejs GJ. Physiological role of somatostatin in the digestive tract: Gastric acid secretion, intestinal absorption, and motility. Scand J Gastroenterol 1986; 21: 47–53, (Suppl. 119)
   PubMed Web of Science ®Google Scholar
• Vinik A I, Gaginella T S, O'Dorisio T M, et al. The distribution and characterization of somatostatin-like immunoreactivity in epithelial cells, submucosa, and muscle of the rat stomach and intestine. Endocrinology 1981; 109: 1921–6
   PubMed Web of Science ®Google Scholar
• Bauer W, Briner U, Doepfner W, et al. SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133–40
   PubMed Web of Science ®Google Scholar
• Kvols L K, Moertel C G, O'Connell M J, Schutt A J, Rubin J., Hahn RG. Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315: 663–6
   PubMed Web of Science ®Google Scholar
• Kvols L K, Buck M, Moertel C G, et al. Treatment of metastatic islet cell carcinoma with a somatostain analogue (SMS 201–996). Ann Intern Med 1987; 107: 162–8
   PubMed Web of Science ®Google Scholar
• Kvols LK., Buck M. Chemotherapy of metastatic carcinoid and islet cell tumors. A review. Am J Med 1987; 82: 77–83
   PubMed Web of Science ®Google Scholar
• Ahlman H, Tisell L-E. The use of a long-acting somatostatin analogue in the treatment of advanced endocrine malignancies with gastrointestinal symptoms. Scand J Gastroenterol 1987; 22: 938–42
   PubMed Web of Science ®Google Scholar
• Richter G, Stöckmann F, Lembcke B, Conlon J M, Creutzfeldt W. Short-term administration of the somatostatin analogue SMS 201–995 in patients with carcinoid tumours. Scand J Gastroenterol 1986; 21(Suppl. 119)193–8
   PubMedGoogle Scholar
• Stöckmann F, Richter G, Lembcke B, Conlon J M, Creutzfeldt W. Long-term treatment of patients with endocrine gastrointestinal tumours with the somatostatin analogue SMS 201–995. Scand J Gastroenterol 1986; 21: 230–7, (Suppl. 119)
   Web of Science ®Google Scholar
• Öberg K, Eriksson B. Medical treatment of neuroendocrine gut and pancreatic tumors. Acta Oncologica 1989; 28: 425–31
   PubMed Web of Science ®Google Scholar
• Lembcke B, Creutzfeldt W, Schleser S, Ebert R, Shaw C, Koop I. Effect of the somatostatin analogue sandostatin (SMS 201–995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion 1987; 36: 108–24
   PubMed Web of Science ®Google Scholar
• Morisset J. Somatostat In: a potential antigrowth factor for the exocrine pancreas. Regul Pept 1984; 10: 11–2
   PubMedGoogle Scholar
• Chou C-K, Ho L-T, Ting L-P, et al. Selective suppression of insulin-induced proliferation of cultured human hepatoma cells by somatostatin. J Clin Invest 1987; 79: 175–8
   PubMed Web of Science ®Google Scholar
• Klijn J GM, Setyono-Han B, Bakker G H, Henkelman M S, Portengen H, Foekens JA. Effects of somatostatin analog (sandostatin) treatment in experimental and human cancer. Hormonal manipulation of cancer: Peptides, growth factors, and new (anti) steroidal agents, J GM Klijn, et al. Raven Press, New York 1987; 495–568
   Google Scholar
• Reubi JC. Somatostatin receptors as markers for endocrine tumors. JAMA 1987; 257: 3277
   PubMed Web of Science ®Google Scholar
• Lamberts S WJ, Koper J W, Reubi JC. Potential role of somatostatin analogues in the treatment of cancer. Eur J Clin Invest 1987; 17: 281–7
   PubMed Web of Science ®Google Scholar